Actas Dermosifiliogr. 2023 Mar 9:S0001-7310(23)00172-2. doi: 10.1016/j.ad.2023.02.016. Online ahead of print.
ABSTRACT
The advent of biosimilar drugs and their use in routine clinical practice has revolutionized the management of moderate to severe psoriasis and led to changes in the positioning of the existing molecules used to control this condition. Evidence from clinical trials complemented by real-world experience has helped to clarify concepts and has significantly changed the use and positioning of biologic agents in this setting. The present document is an update on the position of the Spanish Psoriasis Working Group regarding the use of biosimilar drugs, which takes into account this new situation.
PMID:36906260 | DOI:10.1016/j.ad.2023.02.016